Ifm_05-may 2022 Instant

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI IFM_05-May 2022

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. One critical finding was an increased risk of

If you are looking for guidance based on this study's results: IFM_05-May 2022

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.